Literature DB >> 24274398

The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.

G Pannone, A Santoro, A Feola, P Bufo, P Papagerakis, L Lo Muzio, S Staibano, F Ionna, F Longo, R Franco, G Aquino, M Contaldo, S De Maria, R Serpico, A De Rosa, C Rubini, S Papagerakis, A Giovane, V Tombolini, A Giordano, M Caraglia, M Di Domenico1.   

Abstract

BACKGROUND: The prognosis of the oral squamous cell carcinoma (OSCC) patients remains very poor, mainly due to their high propensity to invade and metastasize. E-cadherin reduced expression occurs in the primary step of oral tumour progression and gene methylation is a mode by which the expression of this protein is regulated in cancers. In this perspective, we investigated E-cadherin gene (CDH1) promoter methylation status in OSCC and its correlation with Ecadherin protein expression, clinicopathological characteristics and patient outcome.
METHODS: Histologically proven OSCC and paired normal mucosa were analyzed for CDH1 promoter methylation status and E-cadherin protein expression by methylation-specific polymerase chain reaction and immunohistochemistry. Colocalization of E-cadherin with epidermal growth factor (EGF) receptor (EGFR) was evidenced by confocal microscopy and by immunoprecipitation analyses.
RESULTS: This study indicated E-cadherin protein down-regulation in OSCC associated with protein delocalization from membrane to cytoplasm. Low E-cadherin expression correlated to aggressive, poorly differentiated, high grade carcinomas and low patient survival. Moreover, protein down-regulation appeared to be due to E-cadherin mRNA downregulation and CDH1 promoter hypermethylation. In an in vitro model of OSCC the treatment with EGF caused internalization and co-localization of E-cadherin with EGFR and the addition of demethylating agents increased E-cadherin expression.
CONCLUSION: Low E-Cadherin expression is a negative prognostic factor of OSCC and is likely due to the hypermethylation of CDH1 promoter. The delocalization of E-cadherin from membrane to cytoplasm could be also due to the increased expression of EGFR in OSCC and the consequent increase of E-cadherin co-internalization with EGFR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24274398     DOI: 10.2174/1568009613666131126115012

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  25 in total

1.  Reduced expression of E-cadherin and p120-catenin and elevated expression of PLC-γ1 and PIKE are associated with aggressiveness of oral squamous cell carcinoma.

Authors:  Yi Jiang; Liyan Liao; Chandrama Shrestha; Shangli Ji; Ying Chen; Jian Peng; Larry Wang; Eryuan Liao; Zhongjian Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Clinical significance of kallikrein-related peptidase-4 in oral cancer.

Authors:  Petros Papagerakis; Giuseppe Pannone; L I Zheng; Maria Athanassiou-Papaefthymiou; Yashuo Yamakoshi; Howard Stan McGuff; Omar Shkeir; Konstantinos Ghirtis; Silvana Papagerakis
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

3.  Expression of Beta-Catenin, Cadherins and P-Runx2 in Fibro-Osseous Lesions of the Jaw: Tissue Microarray Study.

Authors:  Giuseppe Pannone; Riccardo Nocini; Angela Santoro; Francesca Spirito; Pier Francesco Nocini; Silvana Papagerakis; Renny T Franceschi; Marina Di Domenico; Angelina Di Carlo; Nana Danelia; Lorenzo Lo Muzio
Journal:  Biomolecules       Date:  2022-04-16

4.  Loss of E-Cadherin Expression Correlates With Ki-67 in Head and Neck Squamous Cell Carcinoma.

Authors:  Cristina Stefania Dumitru; Amalia Raluca Ceausu; Serban Comsa; Marius Raica
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

5.  E-cadherin expression and prognosis of oral cancer: a meta-analysis.

Authors:  Sheng-Lei Luo; Yong-Gang Xie; Zhen Li; Jia-Hai Ma; Xin Xu
Journal:  Tumour Biol       Date:  2014-02-27

6.  The Role of E-Cadherin as a Prognostic Biomarker in Head and Neck Squamous Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Javad Yazdani; Mohhamad Ali Ghavimi; Elahe Jabbari Hagh; Farzin Ahmadpour
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

7.  Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.

Authors:  Munawwar Ali Khan; Madhumitha Kedhari Sundaram; Amina Hamza; Uzma Quraishi; Dian Gunasekera; Laveena Ramesh; Payal Goala; Usama Al Alami; Mohammad Zeeshan Ansari; Tahir A Rizvi; Chhavi Sharma; Arif Hussain
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-16       Impact factor: 2.629

Review 8.  Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma.

Authors:  Maurizio Romano; Francesco De Francesco; Giuseppe Pirozzi; Enrico Gringeri; Riccardo Boetto; Marina Di Domenico; Barbara Zavan; Giuseppe A Ferraro; Umberto Cillo
Journal:  Oncoscience       Date:  2015-05-15

9.  Beta-catenin and epithelial tumors: a study based on 374 oropharyngeal cancers.

Authors:  Angela Santoro; Giuseppe Pannone; Silvana Papagerakis; H Stan McGuff; Barbara Cafarelli; Silvia Lepore; Salvatore De Maria; Corrado Rubini; Marilena Mattoni; Stefania Staibano; Ernesto Mezza; Gaetano De Rosa; Gabriella Aquino; Simona Losito; Carla Loreto; Salvatore Crimi; Pantaleo Bufo; Lorenzo Lo Muzio
Journal:  Biomed Res Int       Date:  2014-01-08       Impact factor: 3.411

Review 10.  Interactions between E-cadherin and microRNA deregulation in head and neck cancers: the potential interplay.

Authors:  Thian-Sze Wong; Wei Gao; Jimmy Yu-Wai Chan
Journal:  Biomed Res Int       Date:  2014-08-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.